CL2022000161A1 - Vacuna contra la peste porcina africana - Google Patents

Vacuna contra la peste porcina africana

Info

Publication number
CL2022000161A1
CL2022000161A1 CL2022000161A CL2022000161A CL2022000161A1 CL 2022000161 A1 CL2022000161 A1 CL 2022000161A1 CL 2022000161 A CL2022000161 A CL 2022000161A CL 2022000161 A CL2022000161 A CL 2022000161A CL 2022000161 A1 CL2022000161 A1 CL 2022000161A1
Authority
CL
Chile
Prior art keywords
seq
swine fever
african swine
asfv
polypeptides
Prior art date
Application number
CL2022000161A
Other languages
English (en)
Spanish (es)
Inventor
Linda Dixon
Chris Netherton
Geraldine Taylor
Dave Chapman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022000161A1 publication Critical patent/CL2022000161A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/12011Asfarviridae
    • C12N2710/12034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2022000161A 2019-07-29 2022-01-24 Vacuna contra la peste porcina africana CL2022000161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1910794.5A GB201910794D0 (en) 2019-07-29 2019-07-29 Vaccine

Publications (1)

Publication Number Publication Date
CL2022000161A1 true CL2022000161A1 (es) 2022-10-21

Family

ID=67990353

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000161A CL2022000161A1 (es) 2019-07-29 2022-01-24 Vacuna contra la peste porcina africana

Country Status (15)

Country Link
US (1) US20220273788A1 (https=)
EP (1) EP4003412A1 (https=)
JP (1) JP2022542174A (https=)
KR (1) KR20220041144A (https=)
CN (1) CN114375199A (https=)
AU (1) AU2020322191A1 (https=)
BR (1) BR112022000865A2 (https=)
CA (1) CA3148586A1 (https=)
CL (1) CL2022000161A1 (https=)
CO (1) CO2022001782A2 (https=)
GB (1) GB201910794D0 (https=)
MX (1) MX2022001028A (https=)
PH (1) PH12022550063A1 (https=)
TW (1) TW202118771A (https=)
WO (1) WO2021019232A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373119A (zh) * 2021-06-02 2021-09-10 江西农业大学 一种表达非洲猪瘟病毒三基因缺失重组伪狂犬病毒毒株、构建方法及其应用
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
CN116284261B (zh) * 2023-04-04 2024-04-19 中国人民解放军军事科学院军事医学研究院 一种非洲猪瘟病毒结构蛋白组合物及其制备的疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23544A1 (es) * 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
ES2337113B1 (es) * 2007-04-17 2011-01-24 Centre De Recerca En Sanitat Animal (Cresa) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante.
WO2009008888A1 (en) * 2007-07-10 2009-01-15 Matthias Rath African swine virus polypeptides as vaccines and its therapeutic use thereof
EP2202298A1 (en) * 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
WO2017096341A2 (en) * 2015-12-04 2017-06-08 The Texas A&M University System Adenovirus-vectored multivalent vaccine
RU2654586C2 (ru) * 2016-04-20 2018-05-21 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии", (ФГБНУ ФИЦВиМ) Рекомбинационная кассета, содержащая гены EP153R и EP364R штамма Congo (КК-262) вируса африканской чумы свиней и рекомбинантный штамм ΔСongoCD2v вируса африканской чумы свиней
WO2021176235A1 (en) * 2020-03-06 2021-09-10 The Pirbright Institute Vaccine against african swine fever virus infection

Also Published As

Publication number Publication date
CN114375199A (zh) 2022-04-19
JP2022542174A (ja) 2022-09-29
MX2022001028A (es) 2022-02-23
GB201910794D0 (en) 2019-09-11
AU2020322191A1 (en) 2022-03-03
EP4003412A1 (en) 2022-06-01
PH12022550063A1 (en) 2023-04-12
TW202118771A (zh) 2021-05-16
KR20220041144A (ko) 2022-03-31
BR112022000865A2 (pt) 2022-03-08
CO2022001782A2 (es) 2022-06-21
US20220273788A1 (en) 2022-09-01
WO2021019232A1 (en) 2021-02-04
CA3148586A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
CO2022001782A2 (es) Vacuna contra la peste porcina africana
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
CO2022013121A2 (es) Vacuna 2019-ncov (sars-cov-2)
AR122899A1 (es) Combinación de vacunas
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ES2545895T3 (es) Proteína de fusión anticancerígena
BR112017022298A2 (pt) geranilgeranil pirofosfato sintase
BR112022005143A2 (pt) Desenvolvimento de nova vacina contra a peste suína africana viva atenuada baseada na exclusão do gene i177l
BR112016001192A2 (pt) Vacina contra a raiva
MX2019006894A (es) Plantas con tiempo de floracion acortado.
AR081856A1 (es) Vacuna y metodos para reducir una infeccion por campylobacter
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
MX2019003116A (es) Nueva vacuna contra la gripe porcina.
PE20220429A1 (es) Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a
MX2020001655A (es) Vacuna vph.
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CL2020002373A1 (es) Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422).
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
MX2018002616A (es) Proteina de fusion.
AR091033A1 (es) Metodo para producir 11-des-o-metiltomaimicina recombinante
PE20120116A1 (es) Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)